HC Wainwright Issues Negative Estimate for BCAX Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Bicara Therapeutics in a research note issued to investors on Monday, April 7th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.34). HC Wainwright has a "Buy" rating and a $44.00 price target on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for Bicara Therapeutics' Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.73) EPS.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08).

Several other research analysts have also commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wedbush reaffirmed an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $36.50.

Remove Ads

Bicara Therapeutics Stock Down 0.7 %

Bicara Therapeutics stock traded down $0.08 during midday trading on Thursday, hitting $11.30. 116,968 shares of the company's stock were exchanged, compared to its average volume of 469,232. The firm has a 50-day moving average of $12.74 and a two-hundred day moving average of $16.66. Bicara Therapeutics has a 12 month low of $8.91 and a 12 month high of $28.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BCAX. California State Teachers Retirement System purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $25,000. Spire Wealth Management acquired a new position in Bicara Therapeutics in the 4th quarter valued at $31,000. BNP Paribas Financial Markets purchased a new position in Bicara Therapeutics in the 4th quarter valued at $32,000. Legal & General Group Plc acquired a new stake in Bicara Therapeutics during the 4th quarter worth $33,000. Finally, Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.